posted
If the company gets there increase of 5billion shares I think we will sink to .01 before we get a good bounce imho. I know investores hate dillution
IP: Logged |
posted
on the pre 14 There is no cumulative voting. A majority of the outstanding shares, or 855,577,279 shares, must be present to hold the annual meeting. As of the record date, Dr. Pandey and his affiliates owned approximately 341,582,556 voting equivalent shares representing approximately 20% of the voting shares.
posted 22 Sep 06 on the def 14 There is no cumulative voting. A majority of the outstanding shares, or 882,609,012 shares, must be present to hold the annual meeting. As of the record date, Dr. Pandey and his affiliates owned approximately 352,343,389 voting equivalent shares representing approximately 20% of the voting shares.
This is where I need help...
INFORMATION ABOUT VOTES NECESSARY FOR ACTION TO BE TAKEN Each stockholder will be entitled to one vote for each share of common stock or its voting stock equivalent held at the record date. Assuming a quorum is present, a plurality of votes cast by the shares entitled to vote in the election of directors will be required to elect each director. Holders of a majority of the shares entitled to vote may approve all other proposed actions.
a legal eye to answer if shareholders are basically only electing directors and then only majority shareholders are voting for the rest.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!?
IP: Logged |
posted
You get to vote on everything. I got my proxy in the mail yesterday. Ill vote at proxyvote.com. Most likley for everything but against the increase in shares
IP: Logged |
posted
Xechem Receives $473,181 SBIR Grant From NIH-NHLBI to Conduct Toxicity Studies of 5-HMF Compound Wednesday October 4, 6:30 am ET
http://biz.yahoo.com/bw/061004/20061004005285.html?.v=1 NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Xechem International, Inc. (OTC BB: XKEM - News) announced today that it has received a SBIR grant in the amount of $473,181 from the National Institutes of Health, National Heart, Lung and Blood Institute (NIH-NHLBI) to carry out the toxicity studies on the five-membered heterocyclic anti-sickling compound known as 5-HMF. Researchers from both Virginia Commonwealth University (VCU) and Children's Hospital of Philadelphia (CHOP), University of Pennsylvania are expected to participate in the 5-HMF trials. ADVERTISEMENT
As previously reported, Xechem acquired the exclusive worldwide rights for 5-HMF in December 2005 under a license agreement with VCU and on May 26th, 2006, Xechem was successful in obtaining Orphan Drug designation from the US Food and Drug Administration (FDA) for the drug. Research led by Dr. Donald Abraham of VCU has shown 5-HMF to be "the best potential anti-sickling agent in 30 years of sickle cell research," performed by his group. 5-HMF not only is a natural product with very little, if any, toxicity, but it has a high affinity for sickle cell hemoglobin. It is also very active in genetically modified mice as shown by Dr. Toshio Asakura, and his colleagues at the NIH-NHLBI Sickle Cell Disease Reference Laboratory at CHOP.
According to Xechem's Chairman and CEO, Dr. Ramesh Pandey, "We are very pleased to have received this significant grant to fund the toxicity studies of 5-HMF, which has shown great promise as a new type of anti-sickling agent that interacts specifically with intracellular hemoglobin without interacting with other proteins in the body. The grant award will allow us to immediately move forward on the 5-HMF front as we continue with our ongoing efforts to expand our production capability for our first sickle cell drug (NICOSAN(TM)), which was launched in Nigeria on July 6th, 2006."
5-HMF is a single compound which, subject to further testing and trials, could be effective for intravenous and/or oral use in the fight against Sickle Cell Disease. Previously, the Company acquired the exclusive worldwide license from the National Institute for Pharmaceutical Research and Development (NIPRD), Ministry of Health, Federal Government of Nigeria, for the research, development, manufacture, marketing and distribution of NICOSAN(TM)/HEMOXIN(TM), an all Natural Herbal Drug (phyto-pharmaceutical) that was launched in Nigeria on July 6th, 2006.
About Sickle Cell Disease
Sickle Cell Disease (SCD) is an inherited blood disorder caused by an abnormality in the hemoglobin molecule. Patients with the disease often produce stiff, abnormally shaped red blood cells that often do not flow freely through the blood vessels. This can create clogs in the vessels, which in turn can cut off the flow of normal hemoglobin and oxygen to parts of the body, and can cause severe painful attacks or "crises", damage to various organs and shortened life spans. People with SCD often suffer unpredictable painful crises several times a year lasting from a few hours to a week or more. In the US, there are approximately 80,000 patients with SCD. In Nigeria, that number is believed to be approximately 4 million, with an estimated 10 - 12 million sufferers throughout the African continent. Worldwide, at least 16 million individuals are believed to be afflicted with SCD.
About Xechem
Xechem International is a development stage biopharmaceutical company working on Sickle Cell Disease (SCD), antimalarials, and antiviral (including AIDS), anticancer, antifungal and antibacterial products from natural sources, including microbial and marine organisms. Its focus is on the development of phyto-pharmaceuticals (Natural Herbal Drugs) and other proprietary technologies, including those used in the treatment of orphan diseases. Xechem's mission is to bring relief to the millions of people who suffer from these diseases. Its recent focus and resources have been directed primarily toward the development and launch of NICOSAN(TM) (named HEMOXIN(TM) in the US and Europe) for the prophylactic management of Sickle Cell Disease (SCD). With the recent Nigerian regulatory approval of NICOSAN(TM), Xechem is now scaling-up the commercialization of the drug in Nigeria and making preparations for the pursuit of US FDA and European regulatory approval.
Forward Looking Statements
This press release contains certain forward looking statements within the meaning of Section 27A of the Securities Act of 1933 as amended, and section 21E of the Securities and Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward looking statements involve known and unknown risks and uncertainties.
Contact: Xechem International, Inc. Stephen Burg, 707-425-8855
-------------------------------------------------------------------------------- Source: Xechem International, Inc.
IP: Logged |
Today’s Price Performance as of 11:52am EDT, 10/04/2006 Option Chains Margin Requirements Interactive Chart
Loading Chart1 Day | 5 Day | 6 Mo | 1 Yr | 3 Yr | 5 Yr $0.027 Last Price 0.0012 +4.65% Today’s Change $0.03 Today’s Open 20,661,353 Above Avg. Today’s Volume
-------------------- All I say is IMHO.
I like these calm little moments before the storm... Reminds me of Bethoven
IP: Logged |
quote:Originally posted by pepsiman: Any particular reason why XKEM is not going trough the roof
everyone has their guards up. I would think the grant would spark a lot of attention. Need to check with the universities and see what kind of info can be had without too many phone calls (LMAO). Going into a run right before a major split? That could be the main reason pepsi.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!?
IP: Logged |
posted
Boo, with the O/S where it is now...we won't get any major gains that hold until we start getting those 100 million volume days again...I've got a feeling we'll be getting them soon though...
IP: Logged |
posted
I'm sure they won't be happy since the plan is to usee those shares to lure some experienced people to come in and help run the company...I think it will be approved...
IP: Logged |
I agree I think it will be approved, which I do not like the idea of it. Hell, if the company had a great product, then that would speak for itself, and they would not need to "bribe w/shares" good talent to the company. I would think he/she would want to work for XKEM knowing that either:
1. They are doing a good deed for all those in need with this disease. 2. Or that they believe that this company is going to do great things, and believe in the company long term.
Why do they need to offer 100,000,000 shares to someone to come to their company if the product or company speaks for itself? This is why I think Xechem is kinda in limbo... I hope they don't dilute this thing when they do get approval, for the sake of "luring" talent.
Ohh, and I am still in this long, I bought in at .013.
posted
I agree we need the volume to get this moving. One thing about a stock like this IMO many bash it but many are also watching. Picture today’s PR without the upcoming proxy and almost certain increase to 5B with the award program. File an 8k that shows that grant. Instead buyers now would be watching their shares get diluted once the proxy is approved hence IMO the reason why this is only budging. But on the good side... Good timing on releasing the news for loan approval - which could happen any day would show major support. I would also keep an eye on institutional buying. Universities wouldn't sponsor this without out some DD of their own eh? I don't see the run because of the proxy. That’s just my thought. The past 14 and 8ks have set the staff up pretty well. I'm on a wait and see now. I keep searching for new news, from outside of XKEM and still pretty quiet out there. I should add also they need to clean house a bit too, pink sheets co. info share structure is off the chart. Transparency will go a long way. Having a good share structure visible even if only on their own home page would be a beginning.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!?
IP: Logged |
posted
Talked to Steve Burg This monrning.In a nut shell our conversation consisted of the following: That they are NOT seeking approval for more shares to dilute the stock, these shares are not going on the open market,not yet any way. They need the shares as part of their hiring program. They will be given to employees over a two to three year program as a means to not only get new employees but also retain them for a long time. Of the remaining shares I believe will be a back up to the loans they are seeking. Of the THREE loans they are after, one he said he was pretty sure they would get. The other two he's not so sure.But he did say that they need a back up plan should thing fall through.Think about it they are in major construction on the new plant. That plant will need employees and scientist to work it. You decide, as for me I picked up another 100,000 at .0275& .0276 I'm in for the long. By the way he said the construction on the new plant is on schedual, should be done end of 1st qtr or beginning of 2nd qtr of next year. lol
IP: Logged |
posted
nice work pepsi...I thought that there were only 2 loans in the works....do you know how much the third one is for and who it is from?
IP: Logged |
posted
that was 100,000.00 . 50,000.00 at .0275 and the other 50,000.00 at .0276 . what does it matter. The point I wanted to make was my conversation with Mr. Burg.And in doing my DD found that things were not as bad as some of the previous post made out to be. By the way a previous purchase of 150,000.00 shares of XKEM added to what was just purchased as well as more shares if I can swing it says I'm into this company and I do my DD.
IP: Logged |
quote:Originally posted by pepsiman: Talked to Steve Burg This monrning.In a nut shell our conversation consisted of the following: That they are NOT seeking approval for more shares to dilute the stock, these shares are not going on the open market,not yet any way. They need the shares as part of their hiring program. They will be given to employees over a two to three year program as a means to not only get new employees but also retain them for a long time. Of the remaining shares I believe will be a back up to the loans they are seeking. Of the THREE loans they are after, one he said he was pretty sure they would get. The other two he's not so sure.But he did say that they need a back up plan should thing fall through.Think about it they are in major construction on the new plant. That plant will need employees and scientist to work it. You decide, as for me I picked up another 100,000 at .0275& .0276 I'm in for the long. By the way he said the construction on the new plant is on schedual, should be done end of 1st qtr or beginning of 2nd qtr of next year. lol
thanks
i am buying more tom ... what da heck ,i dont think pps will go under 0.02
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Eek!]](eek.gif)
![[Cool]](cool.gif)
![[Confused]](confused.gif)
![[Big Grin]](biggrin.gif)
